Copyright
©The Author(s) 2016.
World J Gastroenterol. Jan 14, 2016; 22(2): 862-873
Published online Jan 14, 2016. doi: 10.3748/wjg.v22.i2.862
Published online Jan 14, 2016. doi: 10.3748/wjg.v22.i2.862
HCV proteins | Genetic stability | Function | Role in immune responses | HCV vaccines |
Structural proteins | ||||
Core (C): P22 | Stable | Major component of viral nucleocapsid | Target for neutralizing Ab and CMI | Synthetic peptides vaccines; e.g., VAL-44 in mice[66] |
Binds viral RNA during assembly | Block the innate immune response | Recombinant yeast cells (GI-5005) that produce an HCV NS3-Core fusion protein in mice[70] | ||
DNA vaccine: CIGB-230 in humans[100] | ||||
E1: gp 35 envelope glycoproteins | High degree of genetic diversity | Receptor binding and HCV entry into target cells | Target for nAbs | The primary immunogen for vaccinology[8,78] |
E2: gp 70 envelope glycoproteins | Continuous variation allowing viral escape of HCV specific CD8 T cells and nAb and exhaustion of CD8 cell in chronic HCV infection[101] | Recombinant HCV E1E2 glycoproteins in chimpanzees/humans -core/E1/E2 (CIGB-230) in human[13,96,100] | ||
Target for pan-genotypic drug therapy | Fusion proteins containing the entire HCV E1 or E2 sequence that is efficiently co-assembled with the HBV S into particles[82] | |||
E1E2MF59 HCV DNA vaccine in human[8] | ||||
Non-structural proteins | ||||
NS1: p7 small polypeptide | Stable | Ion channel localized to plasma membrane | No assigned role | - |
NS2: p23 | Protease transmembrane protein | NS2/3 cleavage is required for persistent viral infection in chimpanzees | Full-length HCV NS2 protein DNA vaccine in mice[102] | |
HCV Proteins | Genetic stability | Function | Role in immune responses | HCV vaccines |
NS3: p70 | Bifunctional serine protease and RNA helicase | Act as a critical immune regulator during HCV infection[102] | Recombinant yeast cells (GI-5005) that produce an HCV NS3-Core fusion protein in mice[70] | |
NS4A: p8 | Stable | Protease cofactor | Block the innate immune response[103] | Ad vector vaccine ( NS3-NS5B in chimpanzees/humans[25,87] |
DNA vaccine: e.g., | ||||
Chron Vac-c in mice with multiple epitopes; NS3/4a, NS4b, NS5a, and NS5b in Rhesus macaques[84] | ||||
ChronVac-C- NS3/4A-expressing DNA vaccine in human in human[73] | ||||
DNA plasmid vaccine encoding NS3/4a, NS4b, NS5a, and NS5b in Rhesus macaques[28] | ||||
NS4B: p27 | Stable | Proteins | Block the innate immune response[103] | Synthetic peptides vaccines; e.g., VAL-44[66] |
Components of the viral replicase complex | DNA vaccine with multiple epitopes; NS3/4a, NS4b, NS5a, and NS5b in Rhesus macaques[28] | |||
NS5A:p56/58 | Stable | Cofactor for NS5B | Block the innate immune response[103] | In mice: Synthetic peptides vaccines; e.g., VAL-44[67]-NS5a-loaded DCs[89] |
Regulate response to INF-α treatment | Modulate the cellular environment to favor virus replication and persistence[104] | |||
Protects cells from TNF-α-mediated apoptotic death[104] | in Rhesus macaques: DNA vaccine with multiple epitopes; NS3/4a, NS4b, NS5a, and NS5b[28] | |||
NS5B: p68 | Stable | RNA dependent polymerase | No assigned role | DNA vaccine with multiple epitopes; NS3/4a, NS4b, NS5a, and NS5b in Rhesus macaques[28] |
Ad vector vaccine (NS3-NS5B in chimpanzees/humans)[97] |
- Citation: Abdelwahab KS, Ahmed Said ZN. Status of hepatitis C virus vaccination: Recent update. World J Gastroenterol 2016; 22(2): 862-873
- URL: https://www.wjgnet.com/1007-9327/full/v22/i2/862.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i2.862